Wall Street analysts forecast that Inovio Pharmaceuticals, Inc. (NASDAQ:INO) will report sales of $7.75 million for the current quarter, Zacks reports. Two analysts have made estimates for Inovio Pharmaceuticals’ earnings, with estimates ranging from $2.50 million to $12.99 million. Inovio Pharmaceuticals posted sales of $8.51 million during the same quarter last year, which would indicate a negative year over year growth rate of 8.9%. The company is scheduled to issue its next earnings report on Wednesday, March 21st.
According to Zacks, analysts expect that Inovio Pharmaceuticals will report full-year sales of $7.75 million for the current year, with estimates ranging from $35.90 million to $46.42 million. For the next fiscal year, analysts forecast that the firm will report sales of $17.76 million per share, with estimates ranging from $10.00 million to $22.00 million. Zacks’ sales calculations are an average based on a survey of research firms that cover Inovio Pharmaceuticals.
Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.15). Inovio Pharmaceuticals had a negative net margin of 221.55% and a negative return on equity of 72.19%. The company had revenue of $2.60 million for the quarter, compared to analysts’ expectations of $10.27 million. During the same period in the previous year, the firm earned ($0.28) earnings per share. The firm’s revenue for the quarter was down 79.2% on a year-over-year basis.
A number of analysts have commented on INO shares. Citigroup started coverage on shares of Inovio Pharmaceuticals in a report on Friday, October 6th. They set a “buy” rating and a $10.00 target price for the company. BidaskClub cut shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, September 18th. Royal Bank Of Canada started coverage on shares of Inovio Pharmaceuticals in a report on Wednesday, October 18th. They set an “outperform” rating and a $11.00 target price for the company. Zacks Investment Research cut shares of Inovio Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. Finally, HC Wainwright set a $13.00 target price on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, October 17th. Three analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $19.16.
Shares of Inovio Pharmaceuticals (INO) opened at $4.50 on Friday. Inovio Pharmaceuticals has a twelve month low of $4.20 and a twelve month high of $9.86.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Virginia Retirement Systems ET AL purchased a new stake in shares of Inovio Pharmaceuticals in the third quarter worth $101,000. BlueCrest Capital Management Ltd purchased a new stake in shares of Inovio Pharmaceuticals in the second quarter worth $107,000. Neuberger Berman Group LLC purchased a new stake in shares of Inovio Pharmaceuticals in the third quarter worth $115,000. Engineers Gate Manager LP purchased a new stake in shares of Inovio Pharmaceuticals in the third quarter worth $117,000. Finally, Emerald Advisers Inc. PA increased its stake in shares of Inovio Pharmaceuticals by 84.0% in the third quarter. Emerald Advisers Inc. PA now owns 20,323 shares of the biopharmaceutical company’s stock worth $129,000 after purchasing an additional 9,280 shares in the last quarter. 32.27% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This piece was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2017/12/10/zacks-brokerages-expect-inovio-pharmaceuticals-inc-ino-will-announce-quarterly-sales-of-7-75-million.html.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Get a free copy of the Zacks research report on Inovio Pharmaceuticals (INO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.